Clinical Trial Update: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. [Phase 3]

View source ↗

Summary

Phase 3b open-label trial evaluating immunogenicity and safety of Novartis Meningococcal B Recombinant Vaccine given on a 0, 2-month schedule in healthy at-risk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Novartis Meningococcal B Recombinant Vaccine (recombinant meningococcal B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Prevention of the Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-10-31